Current and Emerging Treatments for Non-alcoholic Steatohepatitis

Christian L. Horn; Anvi C. Ta; Nadege T. Gunn

doi:10.1007/s11901-020-00540-y

Current and Emerging Treatments for Non-alcoholic Steatohepatitis

Christian L. Horn
, Anvi C. Ta
, Nadege T. Gunn^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Introduction
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent globally, and its progressive form, non-alcoholic steatohepatitis (NASH), has become a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. Unfortunately, there remains an urgent unmet need for regulatory approved NASH treatments.

Purpose of Review
This review focuses on the current NASH treatment recommendations and critically discusses investigational agents in clinical development.

Recent Findings
Most NASH clinical trials are currently in early phase. Many later phase drugs have already failed to meet key endpoints. Obeticholic acid, elafibranor, cenicriviroc, and resmetirom are currently furthest along in the phase 3 development phase.

Summary
The pursuit to find a treatment for NASH is vital. If one or more agents in late-stage development prove effective, a commercially available medication will help augment the benefits of lifestyle interventions.

Original language	English
Pages (from-to)	391-401
Number of pages	10
Journal	Current Hepatology Reports
Volume	19
Issue number	4
DOIs	https://doi.org/10.1007/s11901-020-00540-y
State	Published - 25 Aug 2020
Externally published	Yes

Access to Document

10.1007/s11901-020-00540-y

Cite this

@article{c4a8d0ef3ef0403cbe698c4d1b9129bd,

title = "Current and Emerging Treatments for Non-alcoholic Steatohepatitis",

abstract = "Introduction Non-alcoholic fatty liver disease (NAFLD) is highly prevalent globally, and its progressive form, non-alcoholic steatohepatitis (NASH), has become a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. Unfortunately, there remains an urgent unmet need for regulatory approved NASH treatments. Purpose of Review This review focuses on the current NASH treatment recommendations and critically discusses investigational agents in clinical development. Recent Findings Most NASH clinical trials are currently in early phase. Many later phase drugs have already failed to meet key endpoints. Obeticholic acid, elafibranor, cenicriviroc, and resmetirom are currently furthest along in the phase 3 development phase. Summary The pursuit to find a treatment for NASH is vital. If one or more agents in late-stage development prove effective, a commercially available medication will help augment the benefits of lifestyle interventions.",

author = "Horn, \{Christian L.\} and Ta, \{Anvi C.\} and Gunn, \{Nadege T.\}",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media, LLC, part of Springer Nature 2020.",

year = "2020",

month = aug,

day = "25",

doi = "10.1007/s11901-020-00540-y",

language = "English",

volume = "19",

pages = "391--401",

journal = "Current Hepatology Reports",

issn = "2195-9595",

publisher = "Springer Nature",

number = "4",

}

TY - JOUR

T1 - Current and Emerging Treatments for Non-alcoholic Steatohepatitis

AU - Horn, Christian L.

AU - Ta, Anvi C.

AU - Gunn, Nadege T.

N1 - Publisher Copyright: © Springer Science+Business Media, LLC, part of Springer Nature 2020.

PY - 2020/8/25

Y1 - 2020/8/25

N2 - Introduction Non-alcoholic fatty liver disease (NAFLD) is highly prevalent globally, and its progressive form, non-alcoholic steatohepatitis (NASH), has become a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. Unfortunately, there remains an urgent unmet need for regulatory approved NASH treatments. Purpose of Review This review focuses on the current NASH treatment recommendations and critically discusses investigational agents in clinical development. Recent Findings Most NASH clinical trials are currently in early phase. Many later phase drugs have already failed to meet key endpoints. Obeticholic acid, elafibranor, cenicriviroc, and resmetirom are currently furthest along in the phase 3 development phase. Summary The pursuit to find a treatment for NASH is vital. If one or more agents in late-stage development prove effective, a commercially available medication will help augment the benefits of lifestyle interventions.

AB - Introduction Non-alcoholic fatty liver disease (NAFLD) is highly prevalent globally, and its progressive form, non-alcoholic steatohepatitis (NASH), has become a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. Unfortunately, there remains an urgent unmet need for regulatory approved NASH treatments. Purpose of Review This review focuses on the current NASH treatment recommendations and critically discusses investigational agents in clinical development. Recent Findings Most NASH clinical trials are currently in early phase. Many later phase drugs have already failed to meet key endpoints. Obeticholic acid, elafibranor, cenicriviroc, and resmetirom are currently furthest along in the phase 3 development phase. Summary The pursuit to find a treatment for NASH is vital. If one or more agents in late-stage development prove effective, a commercially available medication will help augment the benefits of lifestyle interventions.

UR - https://www.scopus.com/pages/publications/85101974925

U2 - 10.1007/s11901-020-00540-y

DO - 10.1007/s11901-020-00540-y

M3 - Article

AN - SCOPUS:85101974925

SN - 2195-9595

VL - 19

SP - 391

EP - 401

JO - Current Hepatology Reports

JF - Current Hepatology Reports

IS - 4

ER -

Current and Emerging Treatments for Non-alcoholic Steatohepatitis

Abstract

Access to Document

Fingerprint

Cite this